AB-FARMA AS: årsregnskap 2024 vs 2023
Slipped into loss, cash halved-plus
approved 2025-06-27; registry 2025-07-29; journal 2025 714802
Summary
What changed
Comparing Årsregnskap 2024 with 2023 for AB-FARMA AS. Revenue 0 NOK → 0 NOK (0.0%). Net result 0 NOK → -40.1k NOK. Equity 30.0k NOK → -20.7k NOK.
Pressures included: operating result weakened; fell into a net loss; equity eroded.
Also worth watching: thin equity buffer; paid-in equity reduced; book investments changed. All figures are taken from the published annual accounts for AB-FARMA AS.
At a glance
Scorecard
What deteriorated
-
↓
Operating result weakened
Operating result 0 NOK → -35.1k NOK. Calculated
-
↓
Fell into a net loss
Net result flipped from 0 NOK profit to a loss of 40.1k NOK. Calculated
-
↓
Equity eroded
Book equity 30.0k NOK → -20.7k NOK (equity ratio 100.0% → -0.3%). Calculated
-
↓
Cash fell
Bank deposits 30.0k NOK → 9 261 NOK (-69.1% YoY). Calculated
Things to notice
-
·
Thin equity buffer
Equity ratio is -0.3% of assets — limited loss-absorbing capacity on a stand-alone basis. Interpretation
-
·
Paid-in equity reduced
Paid-in equity fell 30.0k NOK → 19.4k NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Book investments changed
Investment / intangible book value 0 NOK → 8.00m NOK. Reported fact